Proteus Reports Q1 Revenue of $258K, Below Consensus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Should l Buy QSI?
Reports Q1 revenue $258K, consensus $299K. "We delivered a strong quarter of Proteus execution, achieving the key development milestones we outlined at our Investor & Analyst Day in November 2025. Most notably, we achieved automated sequencing runs on integrated Proteus instruments bringing together all the core elements of the system planned for the launch configuration spanning instrumentation, KinetIQ(TM) Array, Sequencing chemistry and data analysis, all without user intervention once the run is initiated," said Jeff Hawkins, President and Chief Executive Officer. "While there is more work ahead, the momentum we are building across all parts of the Proteus development program is encouraging and reinforces our confidence in the roadmap we are executing."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QSI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QSI
Wall Street analysts forecast QSI stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.981
Low
1.50
Averages
2.67
High
4.00
Current: 0.981
Low
1.50
Averages
2.67
High
4.00
About QSI
Quantum-SI Incorporated is a life sciences company. The Company has designed and developed a hardware, consumable and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins. Its launched product consists of Platinum, the Platinum Analysis Software and consumables. Its flagship protein sequencing instrument, Platinum, is designed to make the power of single-molecule detection and NGPS accessible. Platinum is designed to provide a streamlined workflow compared to legacy MS workflows. Platinum uses its proprietary semiconductor chip that leverages time-domain sequencing with an initial focus on NGPS for an unbiased view of the proteome.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Quantum-Si Q1 2026 Earnings Call Insights
- Revenue and Profit Overview: In Q1 2026, Quantum-Si reported revenue of $258,000 and gross profit of $74,000, resulting in a gross margin of 29%, indicating some progress in consumable sales despite overall revenue falling short of expectations.
- Proteus Platform Progress: Management highlighted the technological advantages of the Proteus platform, noting its superior proteome coverage and signal quality compared to Platinum, with plans to achieve detection of 18 amino acids by the end of 2026, marking a significant milestone in product development.
- 2026 Outlook: The company reiterated its targets for 2026, projecting total revenue of approximately $1 million, adjusted operating expenses of no more than $98 million, and total cash usage of less than $93 million, reflecting a focus on long-term platform adoption.
- Liquidity and Financial Position: As of March 31, 2026, Quantum-Si had $190.4 million in cash and cash equivalents, expected to support operations into Q2 2028, indicating strong financial management and runway for future growth.
See More
Quantum-Si to Participate in H.C. Wainwright BioConnect Investor Conference
- Investor Conference Participation: Quantum-Si will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, showcasing its innovative protein analysis technology, which is expected to attract potential investors and enhance the company's market visibility.
- Executive Meeting Schedule: CEO Jeff Hawkins and CFO Jeff Keyes will hold one-on-one meetings throughout the conference, aiming to engage deeply with investors to bolster confidence and drive future funding opportunities.
- Webcast Availability: The event will feature live and archived webcasts, allowing investors who cannot attend in person to access information, thereby expanding Quantum-Si's investor base and enhancing transparency.
- Platform Technology Advantage: Quantum-Si's platform simplifies traditional multi-step workflows through single-molecule protein analysis, enabling researchers to obtain real-time insights into dynamic functional proteins, which accelerates proteomic discoveries and holds significant market application potential.
See More
Quantum-Si Achieves Milestone in Protein Sequencing with Proteus Instruments
- Technical Milestone: Quantum-Si successfully demonstrated protein sequencing on integrated Proteus™ instruments using the KinetIQ™ Array, which detects 17 amino acids, showcasing rapid technological advancement since December 2025, thereby enhancing the company's competitive edge in protein analysis.
- Fully Automated Process: The sequencing workflow is fully automated from sample preparation to data acquisition, requiring users only to place samples and reagents in the instrument drawer, significantly simplifying operations and improving laboratory efficiency.
- Future Development Plans: Quantum-Si aims to expand the production of Proteus instruments in collaboration with manufacturing partners to support product development and transfer to manufacturing, with a commercial launch anticipated by the end of 2026, further driving market demand.
- Market Potential: By simplifying and accelerating protein analysis workflows, Quantum-Si's technology is expected to expedite proteomic discoveries, meeting the growing research demands and enhancing the company's strategic position in the biotechnology sector.
See More
Quantum-Si to Report Q1 2026 Financial Results on May 7
- Earnings Report Schedule: Quantum-Si will announce its Q1 2026 financial results on May 7, 2026, reflecting the company's commitment to transparency and investor communication, which is expected to attract more investor interest.
- Executive Conference Call: CEO Jeff Hawkins and CFO Jeff Keyes will host a conference call at 4:30 PM ET on the same day to discuss financial results and provide a business update, aiming to bolster investor confidence in the company's future growth.
- Webcast Participation: Investors can join the live webcast of the conference call via the Investors section of the Quantum-Si website, enhancing interaction between the company and its investors and facilitating timely information dissemination.
- Platform Technology Advantage: Quantum-Si's platform simplifies protein analysis through single-molecule detection, improving research efficiency and is expected to drive significant breakthroughs in the proteomics field, thereby strengthening the company's competitive position in the market.
See More
Quantum-Si Showcases New Technology at AACR Conference
- Customer Poster Presentation: Quantum-Si will present two customer posters at the AACR annual meeting from April 17-22, 2026, focusing on DNA repair inhibitors and high-resolution detection of post-translational modifications, showcasing the application potential of its single-molecule protein sequencing technology.
- Technological Innovation: The first poster, led by Dr. Nigel O'Neil, introduces a method combining deep mutational scanning with next-generation protein sequencing aimed at developing therapeutics targeting DNA repair enzymes, highlighting the technology's significance in cancer treatment.
- Application Prospects: The second poster, led by Dr. Gloria Sheynkman, demonstrates the ability to detect multiple post-translational modifications using Quantum-Si's single-molecule protein sequencing technology, indicating the technology's broad application potential in biomarker studies.
- Market Strategy: CEO Jeff Hawkins stated that the company invested significant effort in 2025 to build a pipeline of studies, aiming to enhance market awareness through customer data presentations and lay the groundwork for the upcoming launch of Proteus™.
See More
Quantum-Si Unveils New Research on Human Cohesin Complexes
- Research Publication: Quantum-Si announced the publication of a collaborative study with the University of British Columbia and B.C. Cancer Research Institute on bioRxiv, revealing that human cohesins form complexes in yeast cells, which may impact cancer drug development.
- Technological Value: The study utilized Quantum-Si's single-molecule protein sequencing technology to provide direct, unbiased data demonstrating the assembly of human and yeast cohesin proteins into the same complexes, highlighting the technology's significance in mechanistic biology research.
- Impact on Cancer Research: The dysfunction of cohesins is linked to genomic instability in tumors, and the findings offer new avenues for targeting cancer cells, potentially driving the development of novel anti-cancer therapies.
- Strategic Positioning: Quantum-Si's platform aims to enhance research efficiency by simplifying and accelerating protein analysis workflows, thereby strengthening its market position in the proteomics field and facilitating future commercialization efforts.
See More
Quantum-Si Q1 2026 Earnings Call Insights
- Revenue and Profit Overview: In Q1 2026, Quantum-Si reported revenue of $258,000 and gross profit of $74,000, resulting in a gross margin of 29%, indicating some progress in consumable sales despite overall revenue falling short of expectations.
- Proteus Platform Progress: Management highlighted the technological advantages of the Proteus platform, noting its superior proteome coverage and signal quality compared to Platinum, with plans to achieve detection of 18 amino acids by the end of 2026, marking a significant milestone in product development.
- 2026 Outlook: The company reiterated its targets for 2026, projecting total revenue of approximately $1 million, adjusted operating expenses of no more than $98 million, and total cash usage of less than $93 million, reflecting a focus on long-term platform adoption.
- Liquidity and Financial Position: As of March 31, 2026, Quantum-Si had $190.4 million in cash and cash equivalents, expected to support operations into Q2 2028, indicating strong financial management and runway for future growth.
See More
Quantum-Si to Participate in H.C. Wainwright BioConnect Investor Conference
- Investor Conference Participation: Quantum-Si will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, showcasing its innovative protein analysis technology, which is expected to attract potential investors and enhance the company's market visibility.
- Executive Meeting Schedule: CEO Jeff Hawkins and CFO Jeff Keyes will hold one-on-one meetings throughout the conference, aiming to engage deeply with investors to bolster confidence and drive future funding opportunities.
- Webcast Availability: The event will feature live and archived webcasts, allowing investors who cannot attend in person to access information, thereby expanding Quantum-Si's investor base and enhancing transparency.
- Platform Technology Advantage: Quantum-Si's platform simplifies traditional multi-step workflows through single-molecule protein analysis, enabling researchers to obtain real-time insights into dynamic functional proteins, which accelerates proteomic discoveries and holds significant market application potential.
See More
Quantum-Si Achieves Milestone in Protein Sequencing with Proteus Instruments
- Technical Milestone: Quantum-Si successfully demonstrated protein sequencing on integrated Proteus™ instruments using the KinetIQ™ Array, which detects 17 amino acids, showcasing rapid technological advancement since December 2025, thereby enhancing the company's competitive edge in protein analysis.
- Fully Automated Process: The sequencing workflow is fully automated from sample preparation to data acquisition, requiring users only to place samples and reagents in the instrument drawer, significantly simplifying operations and improving laboratory efficiency.
- Future Development Plans: Quantum-Si aims to expand the production of Proteus instruments in collaboration with manufacturing partners to support product development and transfer to manufacturing, with a commercial launch anticipated by the end of 2026, further driving market demand.
- Market Potential: By simplifying and accelerating protein analysis workflows, Quantum-Si's technology is expected to expedite proteomic discoveries, meeting the growing research demands and enhancing the company's strategic position in the biotechnology sector.
See More
Quantum-Si to Report Q1 2026 Financial Results on May 7
- Earnings Report Schedule: Quantum-Si will announce its Q1 2026 financial results on May 7, 2026, reflecting the company's commitment to transparency and investor communication, which is expected to attract more investor interest.
- Executive Conference Call: CEO Jeff Hawkins and CFO Jeff Keyes will host a conference call at 4:30 PM ET on the same day to discuss financial results and provide a business update, aiming to bolster investor confidence in the company's future growth.
- Webcast Participation: Investors can join the live webcast of the conference call via the Investors section of the Quantum-Si website, enhancing interaction between the company and its investors and facilitating timely information dissemination.
- Platform Technology Advantage: Quantum-Si's platform simplifies protein analysis through single-molecule detection, improving research efficiency and is expected to drive significant breakthroughs in the proteomics field, thereby strengthening the company's competitive position in the market.
See More
Quantum-Si Showcases New Technology at AACR Conference
- Customer Poster Presentation: Quantum-Si will present two customer posters at the AACR annual meeting from April 17-22, 2026, focusing on DNA repair inhibitors and high-resolution detection of post-translational modifications, showcasing the application potential of its single-molecule protein sequencing technology.
- Technological Innovation: The first poster, led by Dr. Nigel O'Neil, introduces a method combining deep mutational scanning with next-generation protein sequencing aimed at developing therapeutics targeting DNA repair enzymes, highlighting the technology's significance in cancer treatment.
- Application Prospects: The second poster, led by Dr. Gloria Sheynkman, demonstrates the ability to detect multiple post-translational modifications using Quantum-Si's single-molecule protein sequencing technology, indicating the technology's broad application potential in biomarker studies.
- Market Strategy: CEO Jeff Hawkins stated that the company invested significant effort in 2025 to build a pipeline of studies, aiming to enhance market awareness through customer data presentations and lay the groundwork for the upcoming launch of Proteus™.
See More
Quantum-Si Unveils New Research on Human Cohesin Complexes
- Research Publication: Quantum-Si announced the publication of a collaborative study with the University of British Columbia and B.C. Cancer Research Institute on bioRxiv, revealing that human cohesins form complexes in yeast cells, which may impact cancer drug development.
- Technological Value: The study utilized Quantum-Si's single-molecule protein sequencing technology to provide direct, unbiased data demonstrating the assembly of human and yeast cohesin proteins into the same complexes, highlighting the technology's significance in mechanistic biology research.
- Impact on Cancer Research: The dysfunction of cohesins is linked to genomic instability in tumors, and the findings offer new avenues for targeting cancer cells, potentially driving the development of novel anti-cancer therapies.
- Strategic Positioning: Quantum-Si's platform aims to enhance research efficiency by simplifying and accelerating protein analysis workflows, thereby strengthening its market position in the proteomics field and facilitating future commercialization efforts.
See More
